

149 mm

10 mm

5 mm

5 mm

Merck Semi Serif Bold  
22 pt

Merck San Serif Pro Bold  
17.6 pt

Merck San Serif Pro  
6 pt

197 mm

MERCK

# PRAXILENE®

## Naftidrofuryl Oxalate

**Compositions**

Each film-coated tablet contains Naftidrofuryl Oxalate 200 mg

**Mode of Action**

Praxilene has been shown to exert a direct effect on intracellular metabolism. Thus it has been demonstrated in men and animals that it produces an increase ATP levels and a decrease of lactic acid levels in ischaemic conditions, evidence for an enhancement of cellular oxidative capacity. Furthermore, Praxilene is a powerful spasmolytic agent.

Naftidrofuryl possesses 5-HT<sub>2</sub> blocking activity and counteracts both the vasoconstrictor effects in animals and the effects promoting platelet aggregation in animals and in man due to Serotonin.

**Indications**

Peripheral vascular disorders - painful symptoms of arteritis, intermittent claudication, night cramps, rest pain, incipient gangrene, trophic ulcers, Raynaud's syndrome, diabetic arteriopathy and acrocyanosis.

**Dosage and administration**

Adult and the elderly :  
1 tablet 3 times daily for a minimum of 3 months, or at the discretion of the Physician.

Children :  
The drug is not indicated for use in children

**Precautions**

Caution should be exercised in patients with severe cardiac insufficiency, conduction disorders and renal or hepatic insufficiency. The possibility of an additive effect occurring between Praxilene and anti-arrhythmic and beta adrenergic blocking drugs should be considered.

The administration of Praxilene may modify the composition of the urine, promoting the formation of calcium oxalate kidney stones. Indeed, the oxalate content is 19 mg per 100 mg of active ingredient. Therefore, a sufficient amount of liquid should be taken during treatment to maintain an adequate level of diuresis.

The administration of Praxilene without liquid before going to bed may cause local oesophagitis. Therefore, it is essential to always take Praxilene with a large glass of water.

Cases of liver damage have been reported. In case of symptoms suggesting liver damage, naftidrofuryl must be discontinued

**Drug Interactions**

Although naftidrofuryl inhibited in vitro metabolic reactions catalysed by certain cytochrome P450 isoenzymes at very high concentrations, it is unlikely that co-administration of Praxilene will result in clinically significant inhibition of cytochrome P450-mediated metabolism of other drugs.

**Pregnancy and lactation**

**Pregnancy**  
This medicine is mainly used in elderly subjects, in whom the risk of pregnancy is inexistant. In the absence of any relevant clinical data, the use of Praxilene is not advisable during pregnancy.

**Lactation**  
In the absence of specific data concerning the excretion of the drug in human milk, Praxilene should not be used by breast-feeding women.

**Side effects**

Praxilene is normally well tolerated in the dosage recommended. Occasionally nausea, diarrhea, vomiting and epigastric pain or skin reactions (skin rash) have been noted. In case of disorders of cardiac rhythm, neurological disorders, inform doctor immediately.

In some patients who took the medicinal product without liquid before going to bed, the capsule became stuck in the throat causing local oesophagitis. In very rare cases, calcium oxalate kidney stones have been noted. Rarely, liver damage has been reported.

**Contraindications**

Praxilene must not be used in the following cases:  
- Certain disorders of cardiac function  
- Atrioventricular block.  
- Patients with a history of hyperoxaluria or recurrent calcium-kidney stones

Praxilene is contra-indicated in patients who show a hypersensitivity to naftidrofuryl or to any excipients.

**Overdosage**

**Symptoms**  
Depression of cardiac conduction, confusion and convulsions may occur.

**Treatment:**  
The stomach should be emptied by gastric lavage and emesis. Activated charcoal may be employed if necessary. Cardiovascular function and respiration should be monitored and, in severe cases, electrical pacemaking or the use of isoprenaline should be considered. Convulsions may be managed by diazepam.

**Presentations**  
Box of 10 x 10 film-coated tablets in blisters

**Storage**  
Store at temperature below 25°C

Harus dengan resep dokter  
"On medical prescription only"

Manufactured by  
PT Merck Tbk, Jakarta, Indonesia  
under license from  
Merck Healthcare KGaA, Darmstadt, Germany

Reg. No. : DKL9415804717B1

Date of revision: 25.09.2017

10470505198V10

**Kode Supplier**

SPECIFICATION		
Material name	: Praxilene 200 FCT Insert	Packing condition, if applicable:
Article No	: 10470505198V10	Length of alufoil : -
Dimension	: 149 x 197 mm	Pcs per roll / sheet : -
Material Quality	: HVS 60 gsm	Pcs perbundle : 100 pcs
		Pcs pershipper : -
Varnish Et Finishing	: -	Other condition : Terlipat
Barcode No.	: -	(eg. <i>Folded leaflet</i> ) Lipat 2, lipat 2 dan lipat 2 tengah
Pharmacode No.	: 126	Hasil lipatan : P x L = 75 mm x 50 mm
Color	: Black (5 x 4 mm)	
		Revision History : Old Design 10470505198V10
		- OPI Project
		Prepared by : ferry
REFERENCE DATE :		File name: Praxilene 200 FCT Insert (10470505198V10)